ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
Dianthus Therapeutics Inc

Dianthus Therapeutics Inc (DNTH)

14.86
-0.75
(-4.80%)
Closed 09 April 6:00AM
14.86
-0.06
(-0.40%)
After Hours: 9:30AM

Empower your portfolio: Real-time discussions and actionable trading ideas.

Key stats and details

Current Price
14.86
Bid
5.98
Offer
19.83
Volume
902,525
14.60 Day's Range 16.66
14.78 52 Week Range 31.97
Market Cap
Previous Close
15.61
Open
16.50
Last Trade
1
@
14.86
Last Trade Time
Financial Volume
US$ 14,231,062
VWAP
15.7681
Average Volume (3m)
305,135
Shares Outstanding
32,125,179
Dividend Yield
-
PE Ratio
-11.00
Earnings Per Share (EPS)
-1.36
Revenue
2.83M
Net Profit
-43.56M

About Dianthus Therapeutics Inc

Dianthus Therapeutics, Inc. is a clinical-stage biotechnology company dedicated to advancing antibody complement therapeutics to treat severe autoimmune diseases. The Company is dedicated to designing and delivering monoclonal antibodies with improved selectivity and potency. The Company has initiat... Dianthus Therapeutics, Inc. is a clinical-stage biotechnology company dedicated to advancing antibody complement therapeutics to treat severe autoimmune diseases. The Company is dedicated to designing and delivering monoclonal antibodies with improved selectivity and potency. The Company has initiated a Phase 2 trial of DNTH103, a potential active C1s inhibitor, in generalized Myasthenia Gravis and plans to initiate additional Phase 2 trials in other neuromuscular indications, including Multifocal Motor Neuropathy and Chronic Inflammatory Demyelinating Polyneuropathy. Its product candidate, DNTH103, is a clinical-stage, highly potent, highly selective and fully human monoclonal immunoglobulin G4 with picomolar binding affinity that is designed to selectively bind only to the active form of the C1s complement protein. DNTH103 is engineered with YTE half-life extension technology, a specific three amino acid change in the Fc domain, and has a pharmacokinetic (PK) profile. Show more

Sector
Pharmaceutical Preparations
Industry
Pharmaceutical Preparations
Headquarters
Wilmington, Delaware, USA
Founded
-
Dianthus Therapeutics Inc is listed in the Pharmaceutical Preparations sector of the NASDAQ with ticker DNTH. The last closing price for Dianthus Therapeutics was US$15.61. Over the last year, Dianthus Therapeutics shares have traded in a share price range of US$ 14.78 to US$ 31.97.

Dianthus Therapeutics currently has 32,125,179 shares in issue. The market capitalisation of Dianthus Therapeutics is US$501.47 million. Dianthus Therapeutics has a price to earnings ratio (PE ratio) of -11.00.

DNTH Latest News

PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
1-2.96-16.610549943917.8218.6414.7849362316.96515694CS
4-8.855-37.3392367723.71524.31514.7843713719.81103275CS
12-8.2-35.559410234223.0625.45514.7830513520.90113332CS
26-11.74-44.135338345926.631.9714.7827518523.08662287CS
52-10.23-40.773216420925.0931.9714.7824729124.49054202CS
1564.4642.884615384610.433.776.5818556124.12393256CS
2604.4642.884615384610.433.776.5818556124.12393256CS

DNTH - Frequently Asked Questions (FAQ)

What is the current Dianthus Therapeutics share price?
The current share price of Dianthus Therapeutics is US$ 14.86
How many Dianthus Therapeutics shares are in issue?
Dianthus Therapeutics has 32,125,179 shares in issue
What is the market cap of Dianthus Therapeutics?
The market capitalisation of Dianthus Therapeutics is USD 501.47M
What is the 1 year trading range for Dianthus Therapeutics share price?
Dianthus Therapeutics has traded in the range of US$ 14.78 to US$ 31.97 during the past year
What is the PE ratio of Dianthus Therapeutics?
The price to earnings ratio of Dianthus Therapeutics is -11
What is the cash to sales ratio of Dianthus Therapeutics?
The cash to sales ratio of Dianthus Therapeutics is 169.55
What is the reporting currency for Dianthus Therapeutics?
Dianthus Therapeutics reports financial results in USD
What is the latest annual turnover for Dianthus Therapeutics?
The latest annual turnover of Dianthus Therapeutics is USD 2.83M
What is the latest annual profit for Dianthus Therapeutics?
The latest annual profit of Dianthus Therapeutics is USD -43.56M
What is the registered address of Dianthus Therapeutics?
The registered address for Dianthus Therapeutics is 1209 ORANGE STREET, WILMINGTON, DELAWARE, 19801
What is the Dianthus Therapeutics website address?
The website address for Dianthus Therapeutics is www.magentatx.com
Which industry sector does Dianthus Therapeutics operate in?
Dianthus Therapeutics operates in the PHARMACEUTICAL PREPARATIONS sector

Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
FMTOFemto Technologies Inc
US$ 3.40
(516.50%)
9.4M
NAOVNanoVibronix Inc
US$ 7.13
(142.52%)
90.89M
ZVSAZyVersa Therapeutics Inc
US$ 1.27
(118.21%)
113.95M
IXHLIncannex Healthcare Ltd
US$ 0.85
(72.35%)
5.39M
SXTP60 Degrees Pharmaceuticals Inc
US$ 2.86
(59.03%)
85.09M
XHGXChange TED Inc
US$ 0.3007
(-66.84%)
7.87M
BJDXBluejay Diagnostics Inc
US$ 2.96
(-60.53%)
2.05M
KIDZClassover Holdings Inc
US$ 1.92
(-51.02%)
290.76k
CVRXCVRx Inc
US$ 6.20
(-46.27%)
4.36M
RLYBRallybio Holdings LLC
US$ 0.2342
(-44.88%)
1.82M
NVDANVIDIA Corporation
US$ 96.30
(-1.37%)
472.27M
SUNESUNation Energy Inc
US$ 0.0302
(-39.60%)
407.49M
BTOGBit Origin Ltd
US$ 0.148
(22.21%)
337.83M
TSLLDirexion Daily TSLA Bull 2X Trust ETF
US$ 6.78
(-10.08%)
277.5M
DMNDamon Inc
US$ 0.01235
(-14.83%)
258.2M